OMET (Gortec 2014-04)
Int J Radiat Oncol Biol Phys. 2024 Nov 28:S0360-3016(24)03651-4. doi: 10.1016/j.ijrobp.2024.11.084.
Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR
Thariat J, Bosset M, Falcoz A, Vernerey D, Pointreau Y, Racadot S, Faivre JC, Castelli J, Guihard S, Huguet F, Chapet S, Tao Y, Borel C, Fayette J, Rambeau A, Ferrand FR, Pechery A, Bourhis J, Sun XS; GORTEC, 4bis rue Emile Zola, Tours.